Not enough data
Dean Rudge's coverage predominantly focuses on the healthcare and pharmaceutical industry, with a specific emphasis on pharmaceutical companies, biosimilars, drug market dynamics, and patent issues. His articles mainly provide announcements from the private sector within this industry.
Given his focus on private sector announcements and press releases in the pharmaceutical space, Dean may be particularly interested in pitches that offer exclusive insights or interviews with key figures at pharmaceutical companies regarding new product launches, legal battles over patents or biosimilars, or strategic business moves such as acquisitions or market entries.
Considering the scientific themes present in his coverage attributes along with topics covered like biosimilars and drug markets suggest he might also be open to pitches featuring expert commentary from researchers or professionals who can speak to advancements within these areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Dean Rudge, Jun By
CinnaGen's first EU approval gives the Iranian biosimilars player a regulated-market foothold, turning an earlier teriparatide setback into a launch platform for Zandoriah across Europe's increasingly competitive Forsteo biosimilar field.
Neion Bio has raised an oversubscribed $23m Series A to advance its Raptor platform, which uses genetically engineered chicken eggs to produce complex biologics, including biosimilars.
Alvotech's $152m financing boosts near-term liquidity after a sharp Q1 cash decline, while funding a biosimilar pipeline that management says is approaching a key US launch inflection point.
Saudi Arabia has finalized biosimilar guidance setting out when strong analytical and PK evidence may replace comparative efficacy trials, aligning the SFDA with a broader global shift toward streamlined biosimilar development.
Outlook Therapeutics is nearing a pivotal FDA decision on Lytenava, raising hopes that the US could soon get its first approved ophthalmic bevacizumab for wet AMD after years of regulatory setbacks.
Teva's TAPI restructuring is drawing labor opposition in Italy as its Villanterio site faces potential closure, while around 250 roles are set to go in Israel, as the API unit remains marked for eventual divestment.
Brazil's Anvisa has approved Celltrion's Eydenzelt and SteinCares' Uztok, adding a second Eylea biosimilar and another Stelara rival as the country's biosimilar market gains policy and regulatory momentum.
Janssen's latest suit adds Alvotech to the US golimumab patent fight, threatening AVT05's planned December approval as biosimilar competition builds around the $1.1bn Simponi franchise.
Adalvo's European DCP filing for generic dolutegravir adds an HIV asset to a growing slate of complex generics, value-added medicines and day-one launch programs spanning antivirals, oncology, dermatology and rare diseases.
Henlius and Organon have launched Bildyos and Tuzemty in Canada, adding two more denosumab biosimilars to an increasingly crowded market while expanding Organon's bone-care and oncology biosimilars portfolio.
